Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes

被引:85
|
作者
Sindelar, JL
Jofre-Bonet, M
French, MT
McLellan, AT
机构
[1] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
[3] Natl Bur Econ Res, Cambridge, MA 02138 USA
[4] London Sch Hyg & Trop Med, London WC2A 2AE, England
[5] Univ London London Sch Econ & Polit Sci, Dept Econ, London WC2A 2AE, England
[6] Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA
[7] Univ Penn, Treatment Res Inst, Dept Psychiat, Philadelphia, PA 19106 USA
关键词
cost-effectiveness analysis; treatment; services; economics;
D O I
10.1016/j.drugalcdep.2003.09.002
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This paper identifies and illustrates the challenges of conducting cost-effectiveness analysis (CEA) of addiction treatments given the multiple important outcomes of substance abuse treatment (SAT). Potential problems arise because CEA is intended primarily for single outcome programs, yet addiction treatment results in a variety of outcomes such as reduced drug use and crime and increased employment. Methodological principles, empirical examples, and practical advice are offered on how to conduct an economic evaluation given multiple outcomes. An empirical example is provided to illustrate some of the conflicts in cost-effectiveness (CE) ratios that may arise across the range of outcomes. The data are from the Philadelphia Target Cities quasi-experimental field study of standard versus "enhanced" (e.g. case management and added social services) drug treatment. Outcomes are derived from of the Addiction Severity Index (ASI), while cost data were collected and analyzed using the Drug Abuse Treatment Cost Analysis Program (DATCAP). While the results are illustrative only, they indicate that cost-effectiveness ratios for each of several different outcomes can produce conflicting implications. These findings suggest that multiple outcomes should be considered in any economic analysis of addiction treatments because focusing on a single outcome may lead to inadequate and possibly incorrect policy inferences. However, incorporating multiple outcomes into a CEA of addiction treatment is difficult. Cost-benefit analysis (CBA) may be a preferable and more appropriate approach in some cases. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [31] Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
    Martins, Paulo
    Vandewalle, Bjorn
    Felix, Jorge
    Capela, Carlos M.
    Cerqueira, Joao J.
    Salgado, Antonio, V
    Ferreira, Diana G.
    Monteiro, Isabel
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 229 - 241
  • [32] Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
    Paulo Martins
    Björn Vandewalle
    Jorge Félix
    Carlos M. Capela
    João J. Cerqueira
    António V. Salgado
    Diana G. Ferreira
    Isabel Monteiro
    PharmacoEconomics - Open, 2023, 7 : 229 - 241
  • [33] COST-EFFECTIVENESS OF OFATUMUMAB IN TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN TURKEY
    Tatar, M.
    Yarci, B.
    Akdemir, A. C.
    Olmez, C.
    Tinaz, E.
    Turanli, M.
    VALUE IN HEALTH, 2023, 26 (12) : S148 - S148
  • [34] Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis
    Anastasie M. Dunn-Pirio
    Benjamin M. Heyman
    Dan S. Kaufman
    Revere P. Kinkel
    Current Treatment Options in Neurology, 2019, 21
  • [35] Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis
    Dunn-Pirio, Anastasie M.
    Heyman, Benjamin M.
    Kaufman, Dan S.
    Kinkel, Revere P.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2019, 21 (10)
  • [36] CALIBRATING BAYESIAN MULTIPLE TREATMENT COMPARISON META-ANALYSIS WITH MULTIPLE COST-EFFECTIVENESS ACCEPTABILITY CURVES
    Thorlund, K.
    Mills, E.
    VALUE IN HEALTH, 2012, 15 (07) : A286 - A286
  • [37] Cost-effectiveness analysis of ponatinib in the treatment of CML in Germany
    Le Coutre, P.
    Hirt, C.
    Lannazzo, S.
    Brenn, J.
    Chiroli, S.
    Oncology Research and Treatment, 2015, 38 : 131 - 132
  • [38] Treatment of depression in Germany An analysis of cost-effectiveness with remission
    Voelkl, M.
    Fritze, J.
    Hoeffler, J.
    Roth, G.
    Ruether, E.
    Schreiber, W.
    Schwarzer, W.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2007, 12 (01): : 35 - 43
  • [39] A cost-effectiveness analysis of olmesartan in the treatment of arterial hypertension
    Lamotte, M.
    Annemans, L.
    Van Loy, R.
    Koch, W.
    VALUE IN HEALTH, 2006, 9 (06) : A347 - A347
  • [40] A Cost-Effectiveness Analysis of Pegcetacoplan for the Treatment of Geographic Atrophy
    Patel, Nimesh A.
    Al-Khersan, Hasenin
    Yannuzzi, Nicolas A.
    Lin, James
    Smiddy, William E.
    OPHTHALMOLOGY, 2024, 131 (02) : 129 - 129